Home/Filings/4/0001209191-21-001718
4//SEC Filing

SCHIERMEIER ANDREW 4

Accession 0001209191-21-001718

CIK 0001652130other

Filed

Jan 4, 7:00 PM ET

Accepted

Jan 5, 8:58 PM ET

Size

14.7 KB

Accession

0001209191-21-001718

Insider Transaction Report

Form 4
Period: 2020-12-31
SCHIERMEIER ANDREW
EVP, Dev and Corp Strategy
Transactions
  • Sale

    Common Stock

    2021-01-05$55.86/sh1,377$76,91916,656 total
  • Exercise/Conversion

    Common Stock

    2020-12-31+4,79218,033 total
  • Award

    Stock Option (right to buy)

    2020-12-31+9,5839,583 total
    Exercise: $20.56From: 2020-12-31Exp: 2028-03-20Common Stock (9,583 underlying)
  • Award

    Restricted Stock Unit (performance-based)

    2020-12-31+4,7924,792 total
    From: 2020-12-31Common Stock (4,792 underlying)
  • Exercise/Conversion

    Restricted Stock Unit (performance-based)

    2020-12-314,7920 total
    From: 2020-12-31Common Stock (4,792 underlying)
Footnotes (4)
  • [F1]Includes 568 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2020.
  • [F2]Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of 4,792 performance-based restricted stock units ("PRSUs") on December 31, 2020.
  • [F3]On May 1, 2018, the reporting person was granted an option to purchase 28,750 shares of common stock pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. The award had performance-based vesting, with one-third of the award vesting upon each achievement of three scientific and regulatory milestones through the calendar year 2020 (the "Performance Milestones"). On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of the option as to 9,583 shares.
  • [F4]On May 1, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs.

Issuer

Intellia Therapeutics, Inc.

CIK 0001652130

Entity typeother

Related Parties

1
  • filerCIK 0001738456

Filing Metadata

Form type
4
Filed
Jan 4, 7:00 PM ET
Accepted
Jan 5, 8:58 PM ET
Size
14.7 KB